Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Pharmacokinetics, Safety, and Tolerability of Anti-SARS-CoV-2 Monoclonal Antibody, Sotrovimab, Delivered Intravenously or Intramuscularly in Japanese and Caucasian Healthy Volunteers.
Journal: Clinical pharmacokinetics
Published: October 09, 2023
Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial.
Journal: Open forum infectious diseases
Published: June 26, 2023
Safety, Virology, Pharmacokinetics, and Clinical Experience of High-Dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-Label Clinical Trial.
Journal: Open forum infectious diseases
Published: June 26, 2023
Population pharmacokinetics and exposure-response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID-19.
Journal: CPT: pharmacometrics & systems pharmacology
Published: November 23, 2022
Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19.
Journal: Journal of patient-reported outcomes
Published: October 17, 2022
Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Journal: JAMA
Published: March 14, 2022
Antibody therapy reverses biological signatures of COVID-19 progression.
Journal: Cell reports. Medicine
Published: February 09, 2022
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.
Journal: The New England journal of medicine
Published: October 27, 2021
Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin.
Journal: Journal of global antimicrobial resistance
Published: August 02, 2021
Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities.
Journal: BMC pulmonary medicine
Published: December 01, 2020
Oral 5-Day Lefamulin for Outpatient Management of Community-Acquired Bacterial Pneumonia: Post-hoc Analysis of the Lefamulin Evaluation Against Pneumonia (LEAP) 2 Trial.
Journal: The Journal of emergency medicine
Published: August 12, 2020
Health-Related Quality of Life as Measured by the 12-Item Short-Form Survey Among Adults With Community-Acquired Bacterial Pneumonia who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials.
Journal: Open forum infectious diseases
Published: May 18, 2020
Last Updated: 09/26/2026